Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 10/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113584 | 0.84 | LPL (0.41) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL30928610 | 0.83 | IDO1 (0.39) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL31394882 | 0.82 | LPL (0.43) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL23633173 | 0.81 | LPL (0.36) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL23638441 | 0.81 | FFAR1 (0.39) | LPLLIPGFFAR1IDO1TDO2 | |
| SCHEMBL31394025 | 0.80 | IDO1 (0.39) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL23529729 | 0.79 | SNCA (0.38) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL17673631 | 0.79 | SNCA (0.36) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL23546464 | 0.79 | LPL (0.35) | ESR2LPLLIPGFFAR1IDO1 | |
| SCHEMBL5076837 | 0.79 | LIPG (0.42) | LPLLIPGIDO1TDO2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287063-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| WO-2022253242-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | 南京正大天晴制药有限公司 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287063-A1 | METHIONINE ADENOSYLTRANSFERASE 2A INHIBITOR | MAT2A, MAT2B, MAT1A | ESR2 2786/4885LPL 2855/4885LIPG 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.